Get the Stockscreener App
18.79
2.94%
-0.57
Arcus Biosciences Inc stock is traded at $18.79, with a volume of 1.16M.
It is down -2.94% in the last 24 hours and down -28.80% over the past month.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
See More
Previous Close:
$19.36
Open:
$19.02
24h Volume:
1.16M
Relative Volume:
0.38
Market Cap:
$2.39B
Revenue:
$236.00M
Net Income/Loss:
$-369.00M
P/E Ratio:
-5.9036
EPS:
-3.1828
Net Cash Flow:
$-489.00M
1W Performance:
-15.05%
1M Performance:
-28.80%
6M Performance:
-25.23%
1Y Performance:
+11.98%
1-Day Range:
$18.43
$19.09
1-Week Range:
$17.43
$24.70
52-Week Range:
$16.41
$31.73
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
18.79 | 2.39B | 236.00M | -369.00M | -489.00M | -3.1828 |
VRTX
Vertex Pharmaceuticals Inc
|
526.70 | 133.50B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
809.72 | 83.36B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
206.10 | 82.28B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
885.57 | 55.69B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.14 | 42.66B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-26 | Initiated | William Blair | Outperform |
| Oct-14-26 | Initiated | JP Morgan | Overweight |
| Sep-16-26 | Initiated | TD Cowen | Buy |
| May-18-26 | Resumed | Truist | Buy |
| Feb-12-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-13-26 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Why is Arcus Biosciences stock sliding today? By Investing.com - Investing.com Canada
Arcus Biosciences Prices $250 Million Common Stock Offering; Shares Down Pre-Bell - marketscreener.com
Arcus Biosciences reports $694M cash for pipeline advancement through pivotal trials - The Clinical Trial Vanguard
Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock - TradingView
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock - Yahoo Finance
Arcus Biosciences (RCUS) Shares Plunge Nearly 20% Amid Clinical Data Release and Stock Offering - GuruFocus
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
Arcus Biosciences stock falls on public offering announcement - Investing.com
Arcus Biosciences slides 20% on stock offering, kidney-cancer data (RCUS:NYSE) - Seeking Alpha
Arcus Biosciences launches public offering of common stock By Investing.com - Investing.com Canada
Citi reiterates buy rating on Arcus Biosciences after stock drops 20% - StreetInsider
Arcus Biosciences launches public offering of common stock - StreetInsider
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm - Morningstar
Arcus Biosciences announces public stock offering - TradingView
A public stock offering has begun at Arcus Biosciences, but its size and completion remain uncertain. - Stock Titan
Arcus Biosciences Drops 5.5% After Truist Securities Maintains Buy - AlphaStreet
Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal - Yahoo Finance
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? - Zacks Investment Research
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research
Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead (NYSE:RCUS) - Seeking Alpha
Arcus stock rises on ARC-20 data for kidney cancer drug (RCUS) - Seeking Alpha
Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer - BioSpace
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance UK
Arcus Biosciences Announces New Employment Inducement Grants - Yahoo Finance
Arcus Biosciences Drops 6.1% Amid Sector-Wide Selling - AlphaStreet
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo! Finance Canada
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage? - Yahoo Finance
Arcus Biosciences stock falls 2.79 percent before ARC-20 data - ad-hoc-news.de
Arcus Biosciences stock gains 1.49 percent ahead of data event - ad-hoc-news.de
Wall Street Zen upgrades Arcus Biosciences stock to Hold - ad-hoc-news.de
How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer Data - Yahoo Finance
Arcus Biosciences (RCUS) Pulls Back 3.13% to $24.44, Testing Key SupportBreak of Structure - siam.in
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance UK
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
Wedbush Reiterates Arcus Biosciences At Outperform, Sets Price Target Of $43, Casdatifan Data Ahead - RTTNews
RCUS Reiterated by Wedbush -- Price Target Maintained at $43.00 - GuruFocus
Gilead Sciences Inc and Arcus Biosciences Inc Post ARC-7 Plenary Q&A Transcript - GuruFocus
Arcus Biosciences, Inc. (RCUS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arcus Biosciences Announces New Employment Inducement Grants - Yahoo! Finance Canada
Arcus Biosciences Announces New Employment Inducement Grants - finance.yahoo.com
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance Singapore
Arcus Biosciences stock trades 16.8 percent below yearly high - AD HOC NEWS
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo Finance
(RCUS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
RCUS Looks 292.6% Overvalued on GF Value™ - GuruFocus
Cantor Fitzgerald reiterates Arcus Biosciences stock rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Arcus Biosciences stock rating - Investing.com
New kidney cancer data from 121 patients will be shared Oct. 20 - Stock Titan
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy - Yahoo Finance
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arcus Biosciences Inc Stock (RCUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Azoy Alexander | Chief Accounting Officer |
Aug 21 '26 |
Sale |
30.00 |
2,827 |
84,810 |
39,581 |
| ALEXANDER AZOY | Officer |
Aug 21 '26 |
Proposed Sale |
29.52 |
2,827 |
83,453 |
0 |
| Jaen Juan C. | President |
Jul 10 '26 |
Sale |
28.62 |
20,067 |
574,288 |
822,240 |
| Juan Jaen | Officer |
Jul 09 '26 |
Proposed Sale |
29.96 |
25,000 |
749,000 |
0 |
| Jaen Juan C. | President |
Jul 09 '26 |
Sale |
30.05 |
48,502 |
1,457,631 |
842,307 |
| Juan Jaen | Officer |
Jun 24 '26 |
Proposed Sale |
28.80 |
50,000 |
1,440,000 |
0 |
| Jaen Juan C. | President |
Jun 24 '26 |
Sale |
29.66 |
6,431 |
190,740 |
890,809 |
| Jaen Juan C. | President |
Jun 23 '26 |
Sale |
27.73 |
15,764 |
437,100 |
897,240 |
| Juan Jaen | Officer |
Jun 22 '26 |
Proposed Sale |
27.23 |
25,000 |
680,750 |
0 |
| Jaen Juan C. | President |
Jun 22 '26 |
Sale |
27.03 |
9,236 |
249,661 |
913,004 |
2.65%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):